Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects

Autor: Gulde, Sebastian, Foscarini, Alessia, April-Monn, Simon L, Genio, Edoardo, Marangelo, Alessandro, Satam, Swapna, Helbling, Daniel, Falconi, Massimo, Toledo, Rodrigo A, Schrader, Jörg, Perren, Aurel, Marinoni, Ilaria, Pellegata, Natalia S

Publikováno v: Cancers; Volume 14; Issue 22; Pages: 5481
Cancers 14:5481 (2022)
Scientia
Gulde, Sebastian; Foscarini, Alessia; April-Monn, Simon L; Genio, Edoardo; Marangelo, Alessandro; Satam, Swapna; Helbling, Daniel; Falconi, Massimo; Toledo, Rodrigo A; Schrader, Jörg; Perren, Aurel; Marinoni, Ilaria; Pellegata, Natalia S (2022). Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects. Cancers, 14(22) MDPI AG 10.3390/cancers14225481

Buparlisib; Combination therapy; Primary human tumoroids Buparlisib; Terapia de combinación; Tumoroides humanos primarios Buparlisib; Teràpia combinada; Tumoroides humans primaris Pancreatic neuroendocrine neoplasms (PanNENs) are the second most co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2226f2fc67567f4cce2dbb99c6d90e67

The novel SSTR3 full agonist ITF2984 shows antitumor properties against pancreatic neuroendocrine tumors (Pan-NETs).

Autor: Bistika M, Marangelo A, Ascione F, Valentini N, Fedeli F, Schrader J, Modena D, Steinkühler C, Pellegata NS

Publikováno v: Neuroendocrinology [Neuroendocrinology] 2024 Dec 28, pp. 1-23. Date of Electronic Publication: 2024 Dec 28.